Aquestive Therapeutics Inc (AQST) Volatility At 6.53%, Should You Add A Position?

Aquestive Therapeutics Inc (NASDAQ: AQST) is 32.67% higher on its value in year-to-date trading and has touched a low of $0.72 and a high of $2.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AQST stock was last observed hovering at around $2.64 in the last trading session, with the day’s gains setting it 0.04%.

Currently trading at $2.68, the stock is 5.68% and 17.10% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing 1.52% at the moment leaves the stock 41.30% off its SMA200. AQST registered 199.78% gain for a year compared to 6-month gain of 33.33%. The firm has a 50-day simple moving average (SMA 50) of $4.26 and a 200-day simple moving average (SMA200) of -$15.98.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a -1.47% loss in the last 1 month and extending the period to 3 months gives it a 56.73%, and is 0.37% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.53% over the week and 7.55% over the month.

Aquestive Therapeutics Inc (AQST) has around 130 employees, a market worth around $178.94M and $48.06M in sales. Profit margin for the company is -25.20%. Distance from 52-week low is 272.22% and -9.15% from its 52-week high. The company has generated returns on investments over the last 12 months (-1868.98%).

Aquestive Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.08 with sales reaching $11.63M over the same period.The EPS is expected to grow by 88.84% this year, but quarterly earnings will post 2.80% year-over-year. Quarterly sales are estimated to grow 8.90% in year-over-year returns.

58 institutions hold shares in Aquestive Therapeutics Inc (AQST), with institutional investors hold 36.74% of the company’s shares. The shares outstanding are 66.77M, and float is at 62.96M with Short Float at 3.01%. Institutions hold 34.93% of the Float.

The top institutional shareholder in the company is Bratton Capital Management, LP with over 9.81 million shares valued at $16.19 million. The investor’s holdings represent 14.70% of the AQST Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 1.56 million shares valued at $2.57 million to account for 2.34% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 1.23 million shares representing 1.84% and valued at over $2.03 million, while Armistice Capital, LLC holds 1.74% of the shares totaling 1.16 million with a market value of $1.91 million.

Aquestive Therapeutics Inc (AQST) Insider Activity

A total of 1 insider transactions have happened at Aquestive Therapeutics Inc (AQST) in the last six months, with sales accounting for 0 and purchases happening 1 times.